Filing Details
- Accession Number:
- 0001209191-22-053003
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-10-06 17:58:39
- Reporting Period:
- 2022-10-04
- Accepted Time:
- 2022-10-06 17:58:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1557746 | Aclaris Therapeutics Inc. | ACRS | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1172252 | N Andrew Schiff | C/O Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-10-04 | 7,700 | $16.01 | 626,755 | No | 4 | S | Indirect | By Aisling Capital IV LP |
Common Stock | Disposition | 2022-10-06 | 37,839 | $16.54 | 588,916 | No | 4 | S | Indirect | By Aisling Capital IV LP |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By Aisling Capital IV LP |
No | 4 | S | Indirect | By Aisling Capital IV LP |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 0 | Direct |
Footnotes
- These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.